Trevi Therapeutics' Engagement in Notable Conferences
Trevi Therapeutics, Inc. (NASDAQ: TRVI) is making strides in the biopharmaceutical landscape, focusing on Haduvio™ (oral nalbuphine ER) aimed at treating chronic cough associated with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). In June, the company will participate in several key conferences, presenting groundbreaking insights and developments.
American Cough Conference: A Platform for Innovation
From June 6 to June 7, Trevi will attend the American Cough Conference. On June 6, at 4:05 p.m. ET, they will deliver an oral presentation detailing the baseline demographics and characteristics from the RIVER trial. This trial evaluates the effectiveness of nalbuphine extended-release tablets specifically in patients suffering from refractory chronic cough. Jennifer Good, the President and CEO, alongside other key executives, will represent Trevi.
Key Representatives
The esteemed representatives include Jennifer Good, President and CEO; James Cassella, Ph.D., Chief Development Officer; Danine Summers, VP of Medical Affairs; and Abbey Nakano, Pharm.D., AD of Medical Affairs, who will share valuable insights regarding the trial's outcomes.
CPDD Annual Scientific Meeting: Exploring Contributions to Science
Following the American Cough Conference, Trevi will also be present at the CPDD 87th Annual Scientific Meeting from June 14 to June 18. During this event, on June 18 at 2:00 p.m. CT, the company will showcase a poster presentation on the assessment of human abuse potential of nalbuphine in non-dependent recreational drug users. Dr. Thomas Sciascia, Co-Founder and Chief Scientific Officer, will represent the company during this particular segment.
Poster Presentation Details
This poster session aims to shed light on critical aspects concerning nalbuphine's potential implications in various contexts, highlighting Trevi's commitment to research and safety in therapeutic applications.
BIO International Convention: Showcasing Corporate Growth
Another major event Trevi will attend is the BIO International Convention from June 16 to June 19. On June 17 at 12:15 p.m. ET, a corporate presentation will feature discussions with Jennifer Good and Farrell Simon, Pharm.D., Chief Commercial Officer, emphasizing Trevi's strategic vision for the future.
Importance of BIO Convention
This convention serves as an vital opportunity for Trevi to engage with fellow innovators and industry leaders, sharing their progress and exploring potential collaborations aimed at enhancing patient care.
About Trevi Therapeutics, Inc.
Trevi Therapeutics is at the forefront of developing Haduvio™, an innovative therapy targeting chronic cough in patients suffering from IPF and RCC. Haduvio is unique in being the first investigational therapy to demonstrate statistically significant reductions in cough frequency among patients during clinical trials. The therapy effectively interrupts the cough reflex pathway, acting as both a kappa agonist and a mu antagonist (KAMA), focusing on opioid receptors essential for managing chronic cough episodes.
Chronic cough remains a prevalent condition, particularly affecting patients with IPF. It can disrupt daily life significantly; studies estimate that patients may cough as frequently as 1,500 times per day, leading to deteriorating health outcomes and diminishing quality of life.
Furthermore, refractory chronic cough impacts millions, necessitating innovative solutions. Trevi's Haduvio, with its unique mechanism of action, represents a promising therapy that could alter treatment landscapes.
Although safety and efficacy evaluations have yet to be completed by regulatory authorities, Trevi is determined to navigate this path, potentially transforming care for those in need.
Frequently Asked Questions
What is Haduvio?
Haduvio™ is an investigational therapy developed by Trevi Therapeutics aimed at treating chronic cough in patients with IPF and RCC.
When is Trevi participating in the American Cough Conference?
Trevi Therapeutics will be at the American Cough Conference from June 6 to June 7, delivering a presentation on their RIVER trial.
Who are the key representatives attending the events?
Jennifer Good, James Cassella, Danine Summers, and Abbey Nakano will represent Trevi at various conferences.
What other conferences will Trevi attend in June?
Trevi will also participate in the CPDD Annual Scientific Meeting and the BIO International Convention during June.
What are the main goals of Trevi attending these conferences?
The main goal is to present their research findings, engage with industry leaders, and explore further collaborations to enhance patient treatment options.
